We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day. This change lagged the S&P 500's 1.06% gain on the day. Meanwhile, the Dow gained 0.93%, and the Nasdaq, a tech-heavy index, added 1.2%.
Shares of the drugmaker witnessed a gain of 7.27% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and the S&P 500's loss of 3%.
The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. The company's earnings per share (EPS) are projected to be $0.58, reflecting a 34.88% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $8.02 billion, up 29.99% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.19 per share and a revenue of $32.03 billion, representing changes of +26.59% and +28%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Novo Nordisk. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 15.07% lower. Novo Nordisk currently has a Zacks Rank of #5 (Strong Sell).
From a valuation perspective, Novo Nordisk is currently exchanging hands at a Forward P/E ratio of 46.61. For comparison, its industry has an average Forward P/E of 14.2, which means Novo Nordisk is trading at a premium to the group.
Also, we should mention that NVO has a PEG ratio of 1.86. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 237, finds itself in the bottom 6% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
Novo Nordisk (NVO - Free Report) closed at $101.15 in the latest trading session, marking a -0.97% move from the prior day. This change lagged the S&P 500's 1.06% gain on the day. Meanwhile, the Dow gained 0.93%, and the Nasdaq, a tech-heavy index, added 1.2%.
Shares of the drugmaker witnessed a gain of 7.27% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and the S&P 500's loss of 3%.
The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. The company's earnings per share (EPS) are projected to be $0.58, reflecting a 34.88% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $8.02 billion, up 29.99% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.19 per share and a revenue of $32.03 billion, representing changes of +26.59% and +28%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Novo Nordisk. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 15.07% lower. Novo Nordisk currently has a Zacks Rank of #5 (Strong Sell).
From a valuation perspective, Novo Nordisk is currently exchanging hands at a Forward P/E ratio of 46.61. For comparison, its industry has an average Forward P/E of 14.2, which means Novo Nordisk is trading at a premium to the group.
Also, we should mention that NVO has a PEG ratio of 1.86. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. NVO's industry had an average PEG ratio of 1.86 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 237, finds itself in the bottom 6% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.